Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

• Status: Completed
• Trial end date: 2011-01-20
• Target enrollment: 0
• Participant gender: All

Summary

To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment of Negative Symptoms (SANS).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shire
• Treatments: Lisdexamfetamine Dimesylate

Criteria

Inclusion Criteria:

• Adults aged 18-55

• Clinically stable Schizophrenia and predominant negative symptoms

• Taking a stable dose of antipsychotic medication

Exclusion Criteria:

• Clinically notable positive symptoms defined by PANSS